Skip to main content

ADC vs. Bispecific Antibody Deal Terms Comparison

ADC Median Upfront
$393M
Total: $2.5B
Bispecific Median Upfront
$348M
Total: $2.2B
ADC Total Deal Value
$2.5B
Royalty: 13.4%-21.9%
Bispecific Total Deal Value
$2.2B
Royalty: 12.9%-21.1%
Model Your Deal

Market Analysis

ADCs and bispecific antibodies represent the two most actively transacted advanced modalities in oncology licensing. At Phase 2, ADC deals carry a median total deal value of $2.5B versus $2.2B for bispecific antibodies. ADC upfront payments average $393M compared to $348M for bispecifics, reflecting differences in manufacturing complexity, platform maturity, and competitive dynamics.

The milestone structures diverge based on modality-specific risk profiles. ADC development milestones average $526M versus $466M for bispecifics. ADC deals emphasize payload-linker optimization and therapeutic index milestones, while bispecific deals focus on mechanism-of-action validation and T-cell engagement safety data. Commercial milestones are comparable: $736M for ADCs versus $652M for bispecifics.

Royalty rate structures differ modestly between the two modalities. ADC base royalties range from 13.4% to 21.9%, while bispecific base royalties range from 12.9% to 21.1%. The bispecific-ADC hybrid modality (bispecific antibody-drug conjugates) is emerging as a new premium category that commands terms exceeding either standalone modality.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

Do ADC deals command a premium over bispecific antibody deals?
At Phase 2, ADC deals average $2.5B total deal value versus $2.2B for bispecifics. The ADC premium reflects the established clinical validation (multiple approved ADCs), payload-driven differentiation potential, and broad target landscape. However, bispecific deals are closing the gap as the modality matures.
How do royalty rates differ between ADC and bispecific deals?
ADC base royalties range from 13.4% to 21.9%, compared to 12.9% to 21.1% for bispecifics. ADC deals tend to include manufacturing cost-sharing provisions that effectively reduce the net royalty, while bispecific deals are more likely to include co-promotion rights that can substitute for higher royalties.
Which modality commands higher upfront payments?
ADCs command $393M median upfront versus $348M for bispecifics at Phase 2. The upfront premium for ADCs is driven by the established manufacturing infrastructure, broader target validation, and the demonstrated blockbuster potential of approved ADCs like Enhertu and Padcev.

Related Benchmarks

ADC Deal Benchmarks

View

Bispecific Antibody Deals

View

Oncology Deal Overview 2026

View

Phase 2 Deal Benchmarks

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating